B
grade
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.
Lanreotide · Nature medicine · 2026Top journal
Not reported in abstract.
Research library
Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.
2560studies indexed1161with human data161registered trials2242carry a numeric findingLibrarian added 7 studies today
Showing 18 studiesSortNewest indexed ▾
B
grade
When Thyrotropin Meets Growth Hormone: Clinical Challenges of a Mixed GH/TSH-Secreting PIT1-Lineage Pituitary Neuroendocrine Tumor
Lanreotide · biorxiv-preprint · 2026 · Case report
Lanreotide treatment reduced IGF-1 and GH levels in a patient with a mixed GH/TSH-secreting PitNET, but persistent disease was observed post-surgery.
IGF-1 decreased from 1128 ng/mL to 846 ng/mL after lanreotide treatment.
A
grade
Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.
Lanreotide · Human vaccines & immunotherapeutics · 2026 · RCT
The Rotarix PCV-free vaccine showed non-inferior seroconversion rates compared to the standard Rotarix, but the geometric mean concentration did not meet non-inferiority criteria.
SCR: 84.9% (Rotarix PCV‑free) vs 88.7% (Rotarix); difference -3.73% (95% CI -6.93, -0.55; p = .0317)
A
grade
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Lanreotide · Nature medicine · 2026 · RCTTop journal
Orforglipron may help maintain weight loss in patients who have previously used injectable obesity treatments, but further studies are needed to confirm its long-term efficacy.
Cohort 1 maintained an MBE of 74.7% body weight reduction with orforglipron vs 49.2% with placebo at week 52, P<0.001.
B
grade
Neuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasm
Lanreotide · biorxiv-preprint · 2023 · Case report
Lanreotide treatment led to a notable reduction in serum CgA levels in a patient with a duodenal neuroendocrine tumor, but this is based on a single case and requires further investigation.
Serum CgA reduced from 3636 to <100 ng/mL after five months.
B
grade
Patient Point of View of the diagnosis, treatment and follow up in acromegaly: Single center study from a tertiary center
Lanreotide · biorxiv-preprint · 2024 · Observational
Acromegaly is often diagnosed late, with overall disease control achieved in 65.5% of patients. Increased awareness among healthcare professionals may help reduce complications.
Overall disease control achieved in 38 patients (65.5%).
C
grade
Heterozygous Men1+/T knockout mice do not develop bronchopulmonary neuroendocrine hyperplasia or neoplasia but bronchial adenocarcinoma
Lanreotide · biorxiv-preprint · 2024 · Observational
This study found no evidence of bronchopulmonary neuroendocrine neoplasia in Men1 knockout mice treated with lanreotide, but did observe cases of pulmonary adenocarcinoma in both treated and untreated groups.
No bronchopulmonary neuroendocrine cell hyperplasia or neoplasia detected in 30 mice evaluated.
B
grade
In vivo and In Vitro Efficacy of Statin Therapy in Combination with Somatostatin Analogues in Advanced Bronchopulmonary Neuroendocrine Tumors
Lanreotide · biorxiv-preprint · 2026 · Observational
Dyslipidemia may negatively impact progression-free survival in patients with advanced BP-NETs, and atorvastatin therapy could offer some benefit, but further validation is needed.
Not reported in abstract.
B
grade
Comparative predictive performance of three machine learning algorithms for acute radiation enteritis risk among patients with cervical cancer undergoing radiotherapy: A prospective cohort study.
Lanreotide · Asia-Pacific journal of oncology nursing · 2026 · Observational · n=386
The Random Forest model showed excellent predictive performance for acute radiation enteritis in cervical cancer patients, but further validation is needed before clinical implementation.
Random Forest model AUC was 0.961.
A
grade
Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.
Lanreotide · Human vaccines & immunotherapeutics · 2026 · RCT · Phase 3 · n=169
In high-risk pregnant women, the RSVPreF3-Mat vaccine showed an acceptable safety profile and induced strong immune responses, but preterm birth rates were similar to placebo.
Preterm birth occurred in 18.2% and 19.7% of participants in the vaccine and placebo groups, respectively.
B
grade
The adiponectin/leptin ratio as a biomarker of adiposopathy and visceral adipose tissue accumulation: sex-specific mechanisms.
Lanreotide · Adipocyte · 2026 · Observational · n=54
The adiponectin/leptin ratio may be a useful biomarker for assessing visceral fat accumulation, especially in postmenopausal women, but further prospective studies are needed to confirm these findings.
ALR inversely associated with VAT area in postmenopausal females, p<0.05.
B
grade
Association of dietary habits and physical activity with the severity of fecal incontinence in patients with colorectal cancer after minimally invasive surgery: An exploratory study.
Lanreotide · Asia-Pacific journal of oncology nursing · 2026 · Observational · n=136
Higher red meat intake may reduce fecal incontinence severity, while prolonged sedentary behavior could increase it in colorectal cancer patients post-surgery.
β = -1.42; 95% CI, -2.71 to -0.12 for red meat intake.
C
grade
Maternal diet shapes neonatal microbiome ontogenesis and neurometabolic resilience.
Lanreotide · Gut microbes · 2026 · Observational · Preclinical
Maternal diets rich in omega-3 fatty acids may positively influence offspring metabolism and neurodevelopment, but further research is needed to confirm these effects in humans.
Not reported in abstract.
B
grade
Projection of lifetime cancer risk from high-resolution chest CT using the LAR model in Fars Province, Iran, during the COVID-19 pandemic.
Lanreotide · Journal of environmental health science & engineering · 2023 · Observational · n=1411
The study estimates a total LAR of 90 lung cancer cases per 100,000 persons due to HRCT exposure during the COVID-19 pandemic, highlighting the need for dose optimization in imaging protocols.
Total LAR for lung cancer was 90 (95% UL, 80 - 116) per 100,000 persons.
D
grade
Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.
Lanreotide · The Journal of clinical endocrinology and metabolism · 2026 · Meta-analysisHigh-impact journal
Paltusotine may be a more effective and better-tolerated treatment option for acromegaly compared to some existing therapies, but further clinical experience is needed to confirm these findings.
Paltusotine demonstrated significantly higher biochemical control vs O-OCT and SC-OCT-D (ORs: 7.34 [1.48-36.07] and 7.85 [1.72, 36.25]).
D
grade
Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database.
Lanreotide · Clinical and translational gastroenterology · 2026 · ObservationalHigh-impact journal
Lanreotide showed a significant reduction in total kidney volume after more than 2 years, but its efficacy compared to octreotide and pasireotide remains uncertain.
-7.8 mL TKV reduction for lanreotide after more than 2 years, 95% CI: -10.2 to -5.4
B
grade
A case of conversion surgery for a pancreatic neuroendocrine neoplasm with tumor seeding-related peritoneal dissemination after endoscopic ultrasound-guided fine-needle biopsy.
Lanreotide · Clinical journal of gastroenterology · 2026 · Case reportHigh-impact journal
Lanreotide therapy maintained stable disease for 18 months in a patient with pancreatic neuroendocrine neoplasm, allowing for successful conversion surgery.
Stable disease maintained for 18 months.
B
grade
Primary hepatic neuroendocrine tumor with multifocal liver involvement: A case report and review of the literature.
Lanreotide · Radiology case reports · 2026 · Case report
This case highlights the rarity of primary hepatic neuroendocrine tumors and the importance of accurate diagnosis and management. Treatment with lanreotide resulted in stable lesions.
Largest hepatic mass measured 195 × 100 × 230 mm.
Showing 18 of 18